MedTrace Logo

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

NCT06447506 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-11-17

No results posted yet for this study

Summary

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

GSK1070806

Participants will receive GSK1070806.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-05
Primary Completion
2025-07-29
Completion
2025-07-29
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Bulgaria
  • Canada
  • China
  • Czechia
  • France
  • Germany
  • Greece
  • Japan
  • Mexico
  • Panama
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06447506 on ClinicalTrials.gov